» Articles » PMID: 36273831

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity

Overview
Specialty Gastroenterology
Date 2022 Oct 23
PMID 36273831
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity.

Methods: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis of the following agents: semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone-bupropion ER, orlistat, phentermine, diethylpropion, and Gelesis100 oral superabsorbent hydrogel. The guideline panel used the evidence-to-decision framework to develop recommendations for the pharmacological management of obesity and provided implementation considerations for clinical practice.

Results: The guideline panel made 9 recommendations. The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m, or ≥27 kg/m with weight-related complications) who have an inadequate response to lifestyle interventions. The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity. The guideline panel suggested against the use of orlistat. The panel identified the use of Gelesis100 oral superabsorbent hydrogel as a knowledge gap.

Conclusions: In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options.

Citing Articles

Hospitalist Recognition and Treatment of Obesity in Inpatients: A Quality Improvement Cohort Study.

Hoppenfeld M, Moss J, Johnson S J Brown Hosp Med. 2025; 3(2):94545.

PMID: 40026791 PMC: 11864445. DOI: 10.56305/001c.94545.


Incidence of metabolic and bariatric surgery among US adults with obesity by diabetes status: 2016-2020.

Cheng Y, Bullard K, Hora I, Belay B, Xu F, Holliday C BMJ Open Diabetes Res Care. 2025; 13(1).

PMID: 39965869 PMC: 11836783. DOI: 10.1136/bmjdrc-2024-004614.


Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis.

Liu L, Li Z, Ye W, Peng P, Wang Y, Wan L EClinicalMedicine. 2025; 79():103020.

PMID: 39834714 PMC: 11743856. DOI: 10.1016/j.eclinm.2024.103020.


Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.

Yahia Y, Abuodeh J, Chandra P, Mohamed E, Zayad A, AbuAfifeh L Obes Surg. 2025; 35(2):496-504.

PMID: 39806256 PMC: 11836173. DOI: 10.1007/s11695-024-07647-x.


Ischemic Jejunitis as a Late Complication of Roux-en-Y Gastric Bypass.

Kimchy A, Khambaty F, Marino G ACG Case Rep J. 2025; 12(1):e01591.

PMID: 39781182 PMC: 11709216. DOI: 10.14309/crj.0000000000001591.